It is so consistent with decades of reports in the literature that without NK and T cells ( called lymphopenia ) the survival rate of patients, regardless of cancer type, is highly significantly reduced with this lymphopenia. We can now change that course. A simple blood test tells if the patient has Lymphopenia. The epiphany since 1990 is that NK cells within us is the first responder that needs to be activated to change the course of cancer. I will try to connect the dots to show how Anktiva is part of a finely orchestrated cancer Bioshield platform to stimulate both the innate ( NK cells) and adaptive ( T cells) immune system … a complex orchestrated dance of proteins in our body .. 35 years of work to get to Memory T cells. Ask your doctor “what is my ALC?” NK CELLS MATTER. ALC levels have been hiding in plain sight for decades in a routine test called CBC ( to measure your blood levels for anemia and neutropenia) and has been overlooked by us as clinicians because no drug existed until now to reverse lymphopenia as measured by ALC ….until Anktiva was approved. This thread begins my attempt to describe the journey of insight and evolutionary change of how we approach the treatment of cancer .. and how we re think what “immunotherapy” really means …checkpoint inhibitors alone like Keytruda is not enough.